Virginia Commonwealth University/Massey Cancer Center
Claim this profile,
Global Leader in Cancer
Global Leader in Leukemia
Conducts research for Tumors
Conducts research for Breast Cancer
Conducts research for Lymphoma
609 reported clinical trials
53 medical researchers
Summary
Virginia Commonwealth University/Massey Cancer Center is a medical facility located in undefined, undefined. This center is recognized for care of Cancer, Leukemia, Tumors, Breast Cancer, Lymphoma and other specialties. Virginia Commonwealth University/Massey Cancer Center is involved with conducting 609 clinical trials across 694 conditions. There are 53 research doctors associated with this hospital, such as Andrew Poklepovic, MD, Sarah W. Gordon, DO, Leslie Randall, MD, and Gita V. Massey.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Leukemia
Global LeaderStage II
CD5 positive
Stage IV
Top PIs
Andrew Poklepovic, MDVirginia Commonwealth University/Massey Cancer Center4 years of reported clinical research
Expert in Cancer
Expert in Tumors
34 reported clinical trials
83 drugs studied
Sarah W. Gordon, DOVirginia Commonwealth University/Massey Cancer Center8 years of reported clinical research
Expert in Lung Cancer
Expert in Cancer
26 reported clinical trials
54 drugs studied
Leslie Randall, MDVCU Massey Cancer Center1 year of reported clinical research
Studies Ovarian Cancer
Studies Cancer
19 reported clinical trials
35 drugs studied
Gita V. MasseyVirginia Commonwealth University/Massey Cancer Center7 years of reported clinical research
Expert in Brain Tumor
Expert in Tumors
17 reported clinical trials
24 drugs studied
Clinical Trials running at Virginia Commonwealth University/Massey Cancer Center
Breast Cancer
Prostate Cancer
Lung Cancer
Cancer
Non-Small Cell Lung Cancer
Squamous Cell Carcinoma
Colorectal Cancer
Multiple Myeloma
Lymphoma
Tumors
Gedatolisib + Fulvestrant +/- Palbociclib
for Advanced Breast Cancer
This trial is testing a combination of drugs to treat advanced breast cancer that has not responded to other treatments. The drugs work by blocking growth signals, breaking down estrogen receptors, and stopping cell division. Tamoxifen is a commonly used drug that blocks estrogen receptors to treat breast cancer, but resistance to it often develops.
Recruiting2 awards Phase 311 criteria
Giredestrant + Hormone Therapy
for Early-Stage Breast Cancer
This trial is testing giredestrant, a medication given after initial treatment to prevent breast cancer from returning. It focuses on patients with a specific type of early-stage breast cancer that is hormone-driven and at higher risk of recurrence. Giredestrant works by blocking the hormone estrogen from helping cancer cells grow. Giredestrant has shown promise in previous studies.
Recruiting2 awards Phase 311 criteria
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Virginia Commonwealth University/Massey Cancer Center?
Virginia Commonwealth University/Massey Cancer Center is a medical facility located in undefined, undefined. This center is recognized for care of Cancer, Leukemia, Tumors, Breast Cancer, Lymphoma and other specialties. Virginia Commonwealth University/Massey Cancer Center is involved with conducting 609 clinical trials across 694 conditions. There are 53 research doctors associated with this hospital, such as Andrew Poklepovic, MD, Sarah W. Gordon, DO, Leslie Randall, MD, and Gita V. Massey.